))
Better Health, Brighter Future for Rare with Dan Curran
Manage episode 378782010 series 3349924
Content provided by n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen), N-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by n-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen), N-Lorem Foundation (Dr. Stan Crooke, Amy Williford, Kim Butler, Andrew Serrano, Jon Magnuson, and Kira Dineen) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Dr. Daniel Curran leads Takeda’s efforts to unlock innovation and deliver transformative medicines in a variety of rare-disease areas. Dan embraces learning from, collaborating with, and meeting members of the rare disease community in an effort to produce treatments that result in better health and a brighter future for rare.
- 2:02 How rare disease is defined at Takeda
- 4:10 Rare disease units at Takeda
- 5:23 How Takeda economically justifies half of their pipeline being rare disease drugs
- 9:06 The price of rare disease drugs is too high
- 12:15 Why rare disease efforts are often associated with hematology
- 14:57 What Dr. Curran enjoys about leading Takeda's rare genetics and hematology therapeutic unit
- 16:42 Dr. Curran's professional journey
- 20:50 Takeda's choice to support n-Lorem
86 episodes
Share
